Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 16;24(1):26. doi: 10.1186/s10194-023-01560-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 10 — Galcanezumab effects on incidence of triggers that were followed by headache in super-responders and super non-responders. A Incidence of all triggers that were followed by headache after galcanezumab treatment in super-responders and super non-responders. Note that after occurrence of, or exposure to triggers, super-responders experienced significantly less headaches than super non-responders (p = 0.0001, DF = 1, Fisher exact). B Incidences of headache following occurrence of, or exposure to each trigger during the 3-month treatment period. Note that in the super non-responders, galcanezumab treatment had no effect on 9/11 triggers, and in the super-responders, it had no effect 3/11 triggers